AstraZeneca for the second quarter reported total revenue of $12.938 billion, which increased by 13% on a Year-on-Year (YoY) basis. Moreover, On a half-year basis, total Revenue was up by 18% YoY, which stood at $25.617 billion. The revenue growth was driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.
On a segment basis, total revenue growth from Oncology, cardiovascular, renal and metabolism (CVRM), ...
Ryand83 楼主 : $罗氏(ADR) (RHHBY.US)$ $阿斯利康 (AZN.US)$
Ryand83 楼主 : 本来是说 400 不是 500。关键是罗氏要把我们搞得一团糟